

PARTICULARS TO APPEAR ON THE OUTER PACKAGE {Cardboard box}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Clevor 30 mg/ml eye drops, solution

2. STATEMENT OF ACTIVE SUBSTANCES

1 ml contains: 30 mg ropinirole.

3. PACKAGE SIZE

For home use:

1 x 0.3 ml single-dose container
2 x 0.3 ml single-dose containers
3 x 0.3 ml single-dose containers
4 x 0.3 ml single-dose containers
5 x 0.3 ml single-dose containers
6 x 0.3 ml single-dose containers
8 x 0.3 ml single-dose containers
10 x 0.3 ml single-dose containers

For clinic use:

1 x 0.6 ml single-dose container
2 x 0.6 ml single-dose containers
3 x 0.6 ml single-dose containers
4 x 0.6 ml single-dose containers
5 x 0.6 ml single-dose containers
6 x 0.6 ml single-dose containers
8 x 0.6 ml single-dose containers
10 x 0.6 ml single-dose containers

4. TARGET SPECIES

Dogs



5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Ocular use.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}

Once opened use within 30 minutes.

9. SPECIAL STORAGE PRECAUTIONS

Store the container in the pouch in order to protect from light.

After opening the pouch, the container should be kept in the pouch to protect from light.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Orion Corporation

14. MARKETING AUTHORISATION NUMBER

Vm 06043/5000

15. BATCH NUMBER

Lot {number}

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE {Pouch label}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Clevor 30 mg/ml eye drops

2. STATEMENT OF ACTIVE SUBSTANCES

30 mg/ml ropinirole

3. TARGET SPECIES

Dogs



4. ROUTES OF ADMINISTRATION

Ocular use.

Read the package leaflet before use.

5. WITHDRAWAL PERIODS

6. EXPIRY DATE

Exp. {mm/yyyy}

Once opened use within 30 minutes.

7. SPECIAL STORAGE PRECAUTIONS

8. NAME OF THE MARKETING AUTHORISATION HOLDER

Orion Corporation

9. BATCH NUMBER

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING
UNITS {Single-dose container label}**

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Clevor



2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

30 mg/ml

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Clevor 30 mg/ml eye drops, solution in single-dose container for dogs

2. Composition

Each ml contains:

Active substance:

Ropinirole 30 mg
(equivalent to 34.2 mg ropinirole hydrochloride)

This veterinary medicinal product is a very slightly yellow to yellow clear solution.

3. Target species

Dogs

4. Indications for use

For induction of vomiting in dogs.

5. Contraindications

Your dog must not be given this medicine if it:

- has decreased consciousness, seizures or other similar neurologic symptoms or difficulties in breathing or swallowing that could make the dog inhale a part of the vomit potentially causing aspiration pneumonia
- has ingested sharp foreign objects, acids or alkalis (e.g. drain or toilet bowl cleaners, household detergents, battery fluids), volatile substances (e.g. petroleum products, essential oils, air fresheners) or organic solvents (e.g. antifreeze, windshield wiper fluids, nail polish remover)
- is hypersensitive to ropinirole or to any of the excipients.

6. Special warnings

Special precautions for safe use in the target species:

The efficacy of the veterinary medicinal product has not been established in dogs weighing less than 1.8 kg, or in dogs under 4.5 months of age or in elderly dogs. Use only according to the benefit-risk assessment by the responsible veterinarian.

This veterinary medicinal product may cause a transient increase in heart rate up to 2 hours after administration. The safety of the product has not been studied in dogs with diagnosed cardiac disease/dysfunction. Use only according to the benefit-risk assessment by the responsible veterinarian.

The safety of this product in dogs with clinical signs due to the ingestion of foreign materials has not been investigated.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

People with known hypersensitivity to ropinirole should avoid contact with the veterinary medicinal product. Administer the veterinary medicinal product with caution.

The veterinary medicinal product should not be administered by pregnant or breast-feeding women. Ropinirole might reduce the level of prolactin, a hormone that stimulates milk production in pregnant or breast-feeding women.

This veterinary medicinal product can cause eye irritation. Administer the product with caution. In case of accidental eye or skin contact, rinse immediately the affected area with plenty of fresh water. If symptoms occur, seek medical advice and show the package leaflet or the label to the physician.

Ingestion of this product may lead to drowsiness, nausea, and/or vomiting.

In order to prevent children from getting access to the product, do not leave the container unattended during the administration procedure. After opening, place the container back into the pouch in case a second dose is necessary. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Pregnancy and lactation:

The safety of this veterinary medicinal product has not been established during pregnancy and lactation in the target species. Ropinirole might reduce the level of prolactin, a hormone that stimulates milk production in pregnant or suckling females. Therefore, use of the product is not recommended during pregnancy or lactation.

Interaction with other medicinal products and other forms of interaction:

Inform your veterinarian if your dog is given other medicines.

Other medicines that have antiemetic properties, such as metoclopramide, chlorpromazine, acepromazine, maropitant or antihistamines may diminish the effectiveness of ropinirole.

Overdose:

The tolerance of this veterinary medicinal product has been tested in dogs up to 5 times the recommended dose. Symptoms of overdose consist of the same signs seen as adverse reactions.

If vomiting or some of the adverse reactions (e.g. redness of the eye, increased heart rate or shivering) are prolonged, contact your veterinarian. The effects of ropinirole can be reversed using a specific antidote such as metoclopramide or domperidone. Maropitant does not reverse the clinical signs related to the pharmacological action of ropinirole.

7. Adverse events

This veterinary medicinal product may cause the following adverse reactions:

Dogs:

Very common (> 1 animal / 10 animals treated):	Increased heart rate ¹ Eye redness ² , Ocular discharge ² , Third eyelid protrusion ² , Blepharospasm ² Lethargy ¹
Common (1 to 10 animals / 100 animals treated):	Vomiting ³ , Diarrhoea ¹ Conjunctival oedema ¹ , Eye itching ¹ Ataxia ¹ , Tremors ¹ Tachypnoea ¹
Uncommon (1 to 10 animals / 1 000 animals treated):	Corneal ulcer

¹Transient mild

²Transient mild or moderate

³Extended vomiting (for more than 60 minutes)

In dogs with extended vomiting and other clinical signs related to the pharmacological action of the active substance (e.g. eye redness, increased heart rate or, tremors), dopamine antagonists such as metoclopramide or domperidone may be used to manage these clinical signs.

Maropitant does not reverse the clinical signs related to the pharmacological action of ropinirole.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:

E-mail: adverse.events@vmd.gov.uk

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

8. Dosage for each species, routes and method of administration

Clevor is administered as eye drops into one or both of the dog's eyes at a dose of 1–8 eye drops, depending on the dog's bodyweight. If the dog does not vomit within 15 minutes after administration of the initial dose, a second dose may be given 15 to 20 minutes after administration of the initial dose. The second dose should be the same number of drops as the initial dose. It is recommended to record the time of first administration.

If the dog does not vomit after the second dose, or if it experiences prolonged vomiting or other side effects, contact the responsible veterinarian for further instructions.

Be careful not to touch the dropper tip after opening the container in case a second dose is necessary.

The following dosing table provides the dose volume in drops to be administered corresponding to the dog's bodyweight.

When a quantity of 2 to 4 drops is to be administered, the dose should be divided between both eyes. For example, for the administration of 3 drops: administer 2 drops into the right eye and 1 drop into the left eye.

When a quantity of 6 or 8 drops is to be administered, the dose should be divided into 2 alternate administrations given 1–2 minutes apart. For example, for the administration of 6 drops: administer 2 drops into the right eye and 2 drops into the left eye, then after 1–2 minutes pause administer a further 1 drop into each eye.

Dog bodyweight (kg)	Number of eye drops
1.8–5	1
5.1–10	2
10.1–20	3
20.1–35	4
35.1–60	6
60.1–100	8

9. Advice on correct administration

The veterinary medicinal product should always be used under direction of a veterinarian both at the clinic and, if evaluated to be appropriate by the responsible veterinarian, at home in an asymptomatic dog having a history of ingesting toxic substances.

See the detailed instructions for administration at the end of this leaflet.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special temperature storage conditions.

Store the container in the pouch in order to protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the label or carton after Exp. The expiry date refers to the last day of that month.

Shelf life after first opening the immediate packaging (pouch and container):
30 minutes.

After opening the pouch, the container should be kept in the pouch to protect from light.

Discard any opened individual pouch or container with any remaining liquid after 30 minutes.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems. These measures should help to protect the environment.

Ask your veterinarian or pharmacist how to dispose of medicines no longer required. These measures should help to protect the environment.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

Vm 06043/5000

Pack sizes: 1, 2, 3, 4, 5, 6, 8 and 10 single-dose containers containing 0.3 ml or 0.6 ml.

Not all pack sizes may be marketed.

15. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder:

Orion Corporation
Orionintie 1
02200 Espoo
Finland

Manufacturer responsible for batch release:

Orion Corporation Orion Pharma
Orionintie 1
FI-02200 Espoo
Finland

Local representatives and contact details to report suspected adverse reactions:

Animalcare Ltd.
Moorside
Monks Cross
York
YO32 9GZ
Tel: + 44 1904487687

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

17. Other information

POM-V

Pharmacodynamic properties

Ropinirole is a full dopamine agonist with high selectivity for the dopamine D₂-like receptor family (D₂, D₃ and D₄ receptors). It induces emesis by activating the D₂-like receptors in the chemoreceptor trigger zone, located in the area postrema, which transmits the information to the emesis centre to trigger vomiting. In a clinical field trial including 100 clinically healthy dogs treated with Clevor, the time from administration to first vomit was 3–37 minutes with a mean time of 12 minutes and median time of 10 minutes. The time between the first to the last vomit was 0–108 minutes (0 if the dog vomited only once) with a mean duration of 23 minutes and a median duration of 16 minutes. Within 30 minutes 95 % of the dogs vomited. An additional dose was administered after 20 minutes to 13 % of the dogs because of lack of efficacy. Three dogs (3 %) did not vomit at all despite an additional dose. 5 % of the dogs in the clinical study received anti-emetic treatment (metoclopramide) since their vomiting persisted for more than 60 minutes.

Clevor 30 mg/ml eye drops, solution is supplied in single-dose containers containing 0.3 ml or 0.6 ml. Each container is sealed in an individual aluminium foil laminate pouch. The pouches are further packed in outer cardboard cartons which contain 1, 2, 3, 4, 5, 6, 8 or 10 single-dose containers, together with the corresponding number of package leaflets.

Instructions for administration



OPENING THE CONTAINER:

Open the container by twisting off the cap. Be careful not to touch the dropper tip after opening the container.



ADMINISTRATION:

Keep the dog's head steady in a slightly upright position. Hold the container in an upright position without touching the eye. Rest your little finger on the forehead of the dog to maintain the distance between the container and the eye. Squeeze the prescribed number of drops into the eye(s).



STORING THE OPENED CONTAINER:

Do not leave the container unattended during the administration procedure. After opening place the container back into the pouch, in case a second dose is necessary.



REPEATED DOSE:

In case the dog does not vomit within 15 minutes after the initial administration, a second dose can be given 15 to 20 minutes after administration of the initial dose. The additional dose should be the same as the initial dose.

Gavin Hall

Approved: 12 December 2025